Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL21555662 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL317585 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL3277654 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL338469 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL34074 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL23012792 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL28062573 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL20668544 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL20668546 | 0.94 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL6443403 | 0.94 | CA4 (0.84) | CA4ALDH1A1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12121691-B2 | Antimicrobial caps for medical connectors | BECTON, DICKINSON AND COMPANY (US) | 2024-10-22 | — | — | US | claimed |
| WO-2023091145-A1 | IMPROVED BIOSYNTHETIC WOUND AND BURN DRESSING WITH SILVER-BASED BROAD ANTIMICROBIAL ACTIVITY | WOODROOF E AUBREY (US) | 2023-05-25 | — | — | WO | claimed |
| EP-4121236-A1 | COMPOSITIONS AND METHODS FOR PARTICLE THREE-DIMENSIONAL PRINTING | Holo, Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| EP-3466481-B1 | ANTIMICROBIAL CAPS FOR MEDICAL CONNECTORS | BECTON DICKINSON CO (US) | 2022-11-02 | — | — | EP | claimed |
| US-20220339424-A1 | ANTIMICROBIAL CAPS FOR MEDICAL CONNECTORS | BECTON, DICKINSON AND COMPANY | 2022-10-27 | — | — | US | claimed |
| US-11357965-B2 | Antimicrobial caps for medical connectors | BECTON, DICKINSON AND COMPANY (US) | 2022-06-14 | — | — | US | claimed |
| WO-2022046930-A1 | ANTIVIRAL AND ANTIMICROBIAL PROTECTIVE FILMS WITH MICROSTRUCTURE DETERRENTS | LUMENCO, LLC (US) | 2022-03-03 | — | — | WO | claimed |
| US-20220063178-A1 | ANTIVIRAL AND ANTIMICROBIAL PROTECTIVE FILMS WITH MICROSTRUCTURE DETERRENTS COMBINED WITH THERMALLY ELASTOMERIC AND EMBEDDED CHEMICAL ANTI-BACTERIAL OR ANTI-VIRAL AGENTS | MICROBEPROOF, LLC | 2022-03-03 | — | — | US | claimed |
| CN-111150931-B | Antibacterial cap for medical connector | 贝克顿·迪金森公司 | 2021-10-19 | — | — | CN | claimed |
| WO-2021188638-A1 | COMPOSITIONS AND METHODS FOR PARTICLE THREE-DIMENSIONAL PRINTING | HOLO, INC. (US) | 2021-09-23 | — | — | WO | claimed |
| US-9060511-B2 | Compositions of dibromomalanomide and their use as biocides | ROHM AND HAAS COMPANY (US) | 2015-06-23 | — | — | US | claimed |
| CN-103068229-B | Dibromomalonamide compositions and their use as biocides | DOW GLOBAL TECHNOLOGIES INC | 2015-05-20 | — | — | CN | claimed |
| EP-2582238-B1 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-06-04 | — | — | EP | claimed |
| US-20130142886-A1 | COMPOSITIONS OF DIBROMOMALANOMIDE AND THEIR USE AS BIOCIDES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-06-06 | — | — | US | claimed |
| EP-2582238-A1 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES | Dow Global Technologies LLC (US) | 2013-04-24 | — | — | EP | claimed |
| CN-103068229-A | Dibromomalonamide compositions and their use as biocides | DOW GLOBAL TECHNOLOGIES LLC | 2013-04-24 | — | — | CN | claimed |
| US-20120225126-A1 | SOLID STATE SYNTHESIS METHOD OF SILVER NANOPARTICLES, AND SILVER NANOPARTICLES SYNTHESIZED THEREBY | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-09-06 | — | — | US | claimed |
| WO-2012021340-A1 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-02-16 | — | — | WO | claimed |
| WO-2006056570-A1 | METHOD FOR PRODUCING LIVE FOOD WATER ORGANISMS IN THE PRESENCE OF AN ANTIBACTERIAL | INVE TECHNOLOGIES NV (BE) | 2006-06-01 | — | — | WO | claimed |
| EP-1658776-A1 | Method for producing live food water organisms in the presence of an antibacterial | Inve Technologies N.V. (BE) | 2006-05-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142886-A1 | COMPOSITIONS OF DIBROMOMALANOMIDE AND THEIR USE AS BIOCIDES | DDT, BCHE, MGAM | CA4 654/4885ALDH1A1 1719/4885CASP1 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.